Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has provided an announcement.
Sumitomo Pharma Co., Ltd. has announced a strategic move involving the transfer of its Asian business to a new subsidiary, with 60% of the shares to be acquired by Marubeni Global Pharma Corporation. This decision is part of Sumitomo Pharma’s efforts to strengthen its financial foundation and achieve sustainable growth by leveraging Marubeni’s global network, with the company set to receive significant financial consideration from the transaction.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd., based in Osaka, Japan, operates in the pharmaceutical industry, focusing on the development and marketing of pharmaceutical products. The company has a significant presence in North America with key products like ORGOVYX®, MYFEMBREE®, and GEMTESA® supporting its revenue.
YTD Price Performance: 33.60%
Average Trading Volume: 662
Technical Sentiment Signal: Hold
Current Market Cap: $1.98B
For a thorough assessment of 4506 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue